Back to results
US 6,673,351 B1Granted
Compositions and methods for the treatment and clinical remission of psoriasis
AssigneeAstralis, LLC
InventorJose Antonio O'Daly
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAstralis, LLC
InventorJose Antonio O'Daly
Estimating the term…
Polypeptides comprising amino acid sequences of particulate antigens isolated from various species of Leishmania protozoa, or immunogenic variants thereof, are disclosed for the treatment and clinical remission of psoriasis. Also disclosed are nucleic acid sequences encoding such polypeptides, vectors incorporating such nucleic acid sequences, methods for genetically engineering microbial host cells to produce such polypeptides, and such recombinant microbial host cells. In another embodiment, immunotherapeutic agents incorporating the polypeptides or the nucleic acid sequences are disclosed for the treatment and clinical remission of psoriasis. In another embodiment, methods for the production of the polypeptides using recombinant microbial host cells are disclosed. Finally, methods for the treatment and clinical remission of psoriasis comprising administration of a pharmaceutical composition comprising one or more of the polypeptides or one or more of the nucleic acid sequences are disclosed. The polypeptides induced a TH1 cellular immune response, a positive intradermic reaction, and a blastogenic response in peripheral blood lymphocytes after clinical remission of lesions. Populations of peripheral blood lymphocytes that are altered in psoriasis patients returned to normal values in patients who received the polypeptides and experienced clinical remission of lesions after treatment.
An immunotherapeutic agent capable of eliciting an immune response to result in abatement of the clinical symptoms of psoriasis, said agent comprising a purified protein extract wherein said purified extract is isolated by diethylaminoethyl Sephadex chromatography of a Nonidet P-40 insoluble particulate antigen fraction derived from isolated killed cells of amastigotes from at least one species of the Leishmania genus, said particulate antigen fraction solubilized with 8 M urea and 0.025 M Tris[hydroxymethyl]aminomethane pH 8.3 applied to diethylaminoethyl Sephadex and eluted with a solution comprising 0.1 M. sodium chloride, 8 M urea and 0.025 M. Tris[hydroxymethyl]aminomethane pH 8.3, said purified protein extract consisting of polypeptides having apparent molecular weights after total reduction and allylation of 73, 80 and 82 kDa.
An immunotherapeutic agent capable of eliciting an immune response to result in abatement of the clinical symptoms of psoriasis, said agent comprising a purified protein extract wherein said purified extract is isolated by diethylaminoethyl Sephadex chromatography of a Nonidet P-40 insoluble particulate antigen fraction derived from isolated killed cells of amastigotes from at least one species of the Leishmania genus, said particulate antigen fraction solubilized with 8 M urea and 0.025 M Tris[hydroxymethyl]aminomethane pH 8.3 applied to diethylaminoethyl Sephadex and eluted with a solution comprising 0.15 M. sodium chloride, 8 M urea and 0.025 M. Tris[hydroxymethyl]aminomethane pH 8.3, said purified protein extract consisting of polyepeptides having apparent molecular weights after total reduction and alkylation of 73, 80 and 82 kDa.
Dependencies are inferred from the claim text.